Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 14.40% is 51% below its 5-year average of 29.55%, near the low end of its 5-year range (0.34%–50.25%).
14.46% above its 12-month average of 12.58%.
Reported quarterly gross margin; no daily interpolation. Q4 FY2025 (2025-12-31): 0.34%.
GROSS MARGIN
14.40%
GROSS MARGIN AVG TTM
12.58%
GROSS MARGIN AVG 3Y
20.59%
GROSS MARGIN AVG 5Y
29.55%
GROSS MARGIN AVG 10Y
20.47%
GROSS MARGIN AVG 15Y
37.50%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+14.46%
CURRENT VS 3Y AVG
-30.05%
CURRENT VS 5Y AVG
-51.27%
CURRENT VS 10Y AVG
-29.66%
CURRENT VS 15Y AVG
-61.60%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
39.56%
median of 701 covered companies
CURRENT VS SECTOR MEDIAN
-63.60%
vs the sector median at left
Market Cap
$64.37M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
50.00%
5Y Avg
66.67%
Market Cap
$63.41M
Gross Margin
70.07%
TTM Avg
73.26%
3Y Avg
61.08%
5Y Avg
58.36%
Market Cap
$66.29M
Gross Margin
99.56%
TTM Avg
98.97%
3Y Avg
49.48%
5Y Avg
32.99%
Market Cap
$62.54M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$67.80M
Gross Margin
49.30%
TTM Avg
49.08%
3Y Avg
46.18%
5Y Avg
47.39%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| InterCure Ltd. (INCR) | $65.15M | 14.40% | 12.58% | 20.59% | 29.55% |
| Pliant Therapeutics, Inc. (PLRX)vs › | $64.37M | 0.00% | 0.00% | 50.00% | 66.67% |
| Cingulate Inc. (CING)vs › | $66.00M | 0.00% | 0.00% | 0.00% | 0.00% |
| Heron Therapeutics, Inc. (HRTX)vs › | $63.41M | 70.07% | 73.26% | 61.08% | 58.36% |
| Alps Group Inc (ALPS)vs › | $64.06M | 32.09% | 26.51% | 26.11% | 26.57% |
| Gossamer Bio, Inc. (GOSS)vs › | $66.29M | 99.56% | 98.97% | 49.48% | 32.99% |
| iBio, Inc. (IBIO)vs › | $67.52M | 100.00% | 100.00% | 75.00% | 39.52% |
| Kalaris Therapeutics Inc (KLRS)vs › | $62.54M | 0.00% | 0.00% | 0.00% | 0.00% |
| Champions Oncology, Inc. (CSBR)vs › | $67.80M | 49.30% | 49.08% | 46.18% | 47.39% |
| Fortress Biotech, Inc. (FBIO)vs › | $69.18M | 62.53% | 65.36% | 65.75% | 64.06% |
Gross Margin
14.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 0.34% |
| 2025-09-30 | 0.34% |
| 2025-06-30 | 30.94% |
| 2025-03-31 | 30.94% |
| 2024-12-31 | 0.35% |
| 2024-09-30 | 0.35% |
| 2024-06-30 | 33.13% |
| 2024-03-31 | 33.13% |
| 2023-12-31 | 24.71% |
| 2023-09-30 | 24.71% |
| 2023-06-30 | 31.86% |
| 2023-03-31 | 32.33% |
| 2022-12-31 | 24.49% |
| 2022-09-30 | 45.95% |
| 2022-06-30 | 45.79% |
| 2022-03-31 | 45.15% |
| 2021-12-31 | 43.12% |
| 2021-09-30 | 35.75% |
| 2021-06-30 | 44.10% |
| 2021-03-31 | 42.85% |
| 2020-12-31 | 50.25% |
| 2020-09-30 | 50.03% |
| 2020-06-30 | 49.13% |
| 2020-03-31 | 37.78% |
| 2019-12-31 | 52.35% |
| 2019-09-30 | 5.31% |
| 2019-06-30 | 4.18% |
| 2019-03-31 | 15.55% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 4.48% |
| 2015-09-30 | 80.00% |
| 2015-06-30 | 58.68% |
| 2015-03-31 | 57.97% |
| 2014-12-31 | 49.42% |
| 2014-09-30 | 60.96% |
| 2014-06-30 | 72.13% |
| 2014-03-31 | 74.61% |
| 2013-12-31 | 83.46% |
| 2013-09-30 | 73.34% |
| 2013-06-30 | 73.45% |
| 2013-03-31 | 78.28% |
| 2012-12-31 | 75.46% |
| 2012-09-30 | 77.37% |
| 2012-06-30 | 74.44% |
| 2012-03-31 | 78.30% |
| 2011-12-31 | 76.04% |
| 2011-09-30 | 76.04% |
| 2011-06-30 | 76.04% |
| 2011-03-31 | 76.04% |
| 2010-12-31 | 76.32% |
| 2010-09-30 | 76.32% |
| 2010-06-30 | 76.32% |
| 2010-03-31 | 76.32% |
